UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 532

Sortiert nach

Catumaxomab: Clinical development and future directions

mAbs, 2010-03, Vol.2 (2), p.129-136

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Future oncology (London, England), 2019-08, Vol.15 (24), p.2795-2805

2019

Link zum Volltext

Verfügbarkeit prüfen

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The lancet oncology, 2017-11, Vol.18 (11), p.1454-1466

2017

Link zum Volltext

Verfügbarkeit prüfen

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.LBA9007-LBA9007

2017

Link zum Volltext

Verfügbarkeit prüfen

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Journal of clinical oncology, 2018-08, Vol.36 (22), p.2244-2250

2018

Link zum Volltext

Verfügbarkeit prüfen

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

International journal of cancer, 2012-05, Vol.130 (9), p.2195-2203

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)

Lung cancer (Amsterdam, Netherlands), 2021-04, Vol.154, p.176-185

2021

Link zum Volltext

Verfügbarkeit prüfen

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9004-9004

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4573-4573

2019

Link zum Volltext

Verfügbarkeit prüfen

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial

Journal of clinical oncology, 2017-06, Vol.35 (18_suppl), p.LBA9007-LBA9007

2017

Link zum Volltext

Verfügbarkeit prüfen

The patient’s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050

Future oncology (London, England), 2021-03, Vol.17 (7), p.783-794

2021

Link zum Volltext

Verfügbarkeit prüfen

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

The cancer journal (Sudbury, Mass.), 2014-01, Vol.20 (1), p.18

2014

Link zum Volltext

Verfügbarkeit prüfen

The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs

Melanoma research, 2013-04, Vol.23 (2), p.159-166

2013

Link zum Volltext

Verfügbarkeit prüfen

ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4595-TPS4595

2014

Link zum Volltext

Verfügbarkeit prüfen

A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8567-8567

2012

Link zum Volltext

Verfügbarkeit prüfen

Management of imatinib-resistant CML patients

Onkologie, 2007-11, Vol.30 (11), p.574

2007

Link zum Volltext

Verfügbarkeit prüfen

Prevention of initial perfusion failure during xenogeneic ex vivo liver perfusion by selectin inhibition

Transplantation, 1998-11, Vol.66 (10), p.1265

1998

Link zum Volltext

Verfügbarkeit prüfen

Ergebnisse der Strahlenbehandlung von malignen Tumoren im Kopf- und Halsbereich

Linke, Rolf

1967

Link zum Volltext

Verfügbarkeit prüfen

Intravital microscopic investigation of xenogeneic microcirculation and impact of complement depletion by cobra venom factor

Xenotransplantation (Københaven), 1998-11, Vol.5 (4), p.262-273

1998

Link zum Volltext

Verfügbarkeit prüfen

Optimization of phagocyte chemiluminescence measurements using microplates and vials

Luminescence (Chichester, England), 1999-03, Vol.14 (2), p.91-98

1999

Link zum Volltext

Verfügbarkeit prüfen

Katathym Imaginative Psychotherapie (KIP)

1st ed., 2016

Link zum Volltext

Verfügbarkeit prüfen

A biophysical explanation for Nd:YAG percutaneous laser disc decompression success

Journal of clinical laser medicine & surgery, 2001-10, Vol.19 (5), p.235-238

2001

Link zum Volltext

Verfügbarkeit prüfen

Myocardial fatty acid metabolism during acute cardiac allograft rejection

Research in experimental medicine, 1998, Vol.197 (5), p.255-262

1998

Link zum Volltext

Verfügbarkeit prüfen

On the calibration of the cohesive strength for cohesive zone models in finite element analyses

Theoretical and applied fracture mechanics, 2023-04, Vol.124, p.103733, Article 103733

2023

Link zum Volltext

Verfügbarkeit prüfen

On the characterisation of cohesive interfaces by the mode I strain energy release ratio

Proceedings in applied mathematics and mechanics, 2023-03, Vol.22 (1), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 532

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(521)

Publikationsform

Sprache

Deutsch
(444)
Englisch
(247)
Japanisch
(8)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Library & Information Science
(180)
E-Book
(179)
Elektronisches Buch
(179)
Engineering
(120)
Social Sciences
(104)
Deutschland
(82)
Economics
(74)
Business And Management
(57)
Aufsatzsammlung
(56)
Economics/management Science
(52)
Education
(51)
Germany
(51)
Social Sciences, General
(50)
Business
(47)
E-Book Springer Geistes- Und Sozialwissenschaften, Recht
(45)
Science & Technology
(43)
Ebooks Springer Geistes- Und Sozialwissenschaften, Recht
(42)
Lehrbuch
(39)
Ebooks Springer Technik Und Informatik
(38)
Mathematics
(36)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Catumaxomab: Clinical development and future directions

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis

Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial

The patient’s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs

ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC)

A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma

Management of imatinib-resistant CML patients

Prevention of initial perfusion failure during xenogeneic ex vivo liver perfusion by selectin inhibition

Ergebnisse der Strahlenbehandlung von malignen Tumoren im Kopf- und Halsbereich

Intravital microscopic investigation of xenogeneic microcirculation and impact of complement depletion by cobra venom factor

Optimization of phagocyte chemiluminescence measurements using microplates and vials

Katathym Imaginative Psychotherapie (KIP)

A biophysical explanation for Nd:YAG percutaneous laser disc decompression success

Myocardial fatty acid metabolism during acute cardiac allograft rejection

On the calibration of the cohesive strength for cohesive zone models in finite element analyses

On the characterisation of cohesive interfaces by the mode I strain energy release ratio

Suchergebnisse filtern